CVS Health (NYSE:CVS) posted its quarterly earnings results on Wednesday. The pharmacy operator reported $1.73 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.68 by $0.05, Briefing.com reports. CVS Health had a return on equity of 15.45% and a net margin of 1.83%. The business had revenue of $66.89 billion during the quarter, compared to the consensus estimate of $64.01 billion. During the same period in the prior year, the company posted $2.14 EPS. The firm’s revenue for the quarter was up 22.9% compared to the same quarter last year. CVS Health updated its FY 2020
Pre-Market guidance to 7.04-7.17 EPS and its FY20 guidance to $7.04-7.17 EPS.

NYSE CVS traded down $1.13 during trading hours on Friday, hitting $70.87. 1,367,728 shares of the company were exchanged, compared to its average volume of 7,091,313. CVS Health has a 52 week low of $51.72 and a 52 week high of $77.03. The company has a quick ratio of 0.61, a current ratio of 0.92 and a debt-to-equity ratio of 1.32. The stock has a 50-day moving average price of $72.71 and a 200 day moving average price of $67.58. The stock has a market cap of $95.30 billion, a PE ratio of 20.97, a price-to-earnings-growth ratio of 1.56 and a beta of 0.93.

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were paid a dividend of $0.50 per share. The ex-dividend date was Wednesday, January 22nd. This represents a $2.00 annualized dividend and a yield of 2.82%. CVS Health’s payout ratio is currently 28.25%.

A number of equities analysts recently weighed in on CVS shares. Mizuho upped their target price on shares of CVS Health from $71.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Cantor Fitzgerald lifted their price target on shares of CVS Health from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday. ValuEngine upgraded shares of CVS Health from a “strong sell” rating to a “sell” rating in a research note on Friday, January 24th. Cfra increased their price objective on shares of CVS Health from $85.00 to $86.00 and gave the company a “strong-buy” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. raised their price objective on CVS Health from $88.00 to $97.00 and gave the company an “overweight” rating in a research report on Thursday, December 19th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $78.48.

In other news, COO Jonathan C. Roberts sold 57,563 shares of CVS Health stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $72.63, for a total value of $4,180,800.69. Following the completion of the transaction, the chief operating officer now owns 102,608 shares in the company, valued at approximately $7,452,419.04. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Larry J. Merlo sold 266,476 shares of CVS Health stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $74.79, for a total value of $19,929,740.04. Following the completion of the transaction, the chief executive officer now owns 703,497 shares of the company’s stock, valued at approximately $52,614,540.63. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 404,182 shares of company stock worth $30,121,266. Company insiders own 0.53% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

Read More: Support Level

Earnings History for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.